• Fresh issue size: It provides a fresh issue size aggregating up to 3,000 million rupees.

• Offer for sale: It provides offer for sale of up to 69,568,204 equity shares of face value of 10.
• Price Range: The price band is fixed between Rs. 382 - 402.00 per equity share.
• Lot size: It offers a lot size of 35 equity shares.
• Issue Type: It is a book built issue.
• Subscription date: The IPO subscription begins from 29th January, 2025 and ends on 31st January, 2025.
• Listing date: The IPO will be listed on 5th February,2025.
• Stock Exchange: The exchange is going to be NSE and BSE

The Company through this IPO proposes to utilize the net proceeds towards repayment of certain borrowings, meet capital for strategic business developments and unidentified inorganic acquisition.

The table below (in millions) shows the financial performance of the company over the last three fiscal years.(for the year ended in March 31, 2024)

India’s health care lags significantly comparing to the other developed countries and it has been the constant endeavour of the Government to strive to improve this drawback with continued investments and strategic interventions towards strengthening the healthcare workforce and improve health outcomes across the nation. India’s GDP is expected to grow at 8.2% in Financial Year 2024 and 6.8% in Financial Year 2025 and the healthcare delivery industry is anticipated to increase at a CAGR 9–11% from Rs. 6.3 trillion in FY2024 to Rs 9.1–9.3 trillion FY 2028.
India is witnessing increasing number of eye related disorders like cataract, retina, cornea, glaucoma, Pterygium, etc based disorders among all age groups, According to the statistics of the International Agency for Prevention of Blindness, India has the largest population of visually impaired persons worldwide, with about one in five Indians suffering from a vision loss disorder.

The government is constantly lending its support with many initiative schemes and awareness camps to address eye related disorder patients.

The Indian eye care industry has shown a remarkable growth increasing at a compound annual growth rate of 11.5 % from 2019 to 2024 and and is further projected to grow at a compound annual growth rate of 12% to 14% from 2024 to 2028. In 2024, the Indian eye care services market was valued at about Rs.378 billion it is expected to hit Rs.550–650 billion by 2028.

• The company has 165 domestic chains across 13 states and 4 union territories in India and 15 outlets across 9 different countries in Africa.

• It offers all kinds of end to end eye care services and has seen substantial growth over the last three fiscal years increasing its income from operations from Rs. 7,137.84 million in 2022 to Rs.13,764.49 million in 2024.
• The company was founded by Dr. Jaiveer Aggrawal, a recipient of Padma Bhushan in medicine and is promoted by Dr. Amar Agarwal, the chairman who has over 35 years of clinical experience in the eye care services industry along with many 667 doctors with ample contributions and experience in the filed of ophthalmology and healthcare.
• The company has received valuable recognition towards its contribution in Healthcare, some notable award conferred upon the company are “Digital Initiative for Patient Education” award by Smart Hospitals and Diagnostic Summit and Awards, 2024, “Most Trusted Eye Hospital Brand in India” award by the Trust Research Advisory Awards, 2023 etc.

• The company’s brand and reputation is of utmost importance, failure to maintain the same reputation and quality due to negative publicity may harm the business operations.

• The company’s major facilities are located in Tamil Nadu (Chennai), Maharashtra and Karnataka any adverse developments in these facilities could result to effect the business operation, financial condition and results of operations.
• The company largely depends on third party suppliers for the supply of equipment (including maintenance services), medical consumables, drugs, etc under various arrangements, any disruption in the chain of supply or failure to maintain these arrangements, may adversely effect the company operations and financial conditions.
• The company is constantly pursuing acquisitions for inorganic growth and failure to acquire these acquisitions in reasonable terms may effect the financial conditions of the business.
• The company has availed certain borrowings and failure to repay these borrowings may adversely effect the financial conditions and business operations.
• The company, its promoters and directors are facing certain pending litigation any outcome of this proceeding may impact the company operations and financial conditions.
• Apart from a wide range of eye services and products provided by the company, The company’s major revenue is generated from eye surgeries and any reduction in patients due to negligence, loss of reputation or standard of operations in the future may adversely effect the business operation and financial conditions. 
• There is a growing competition in this sector with many well established businesses like Apollo Healthcare, Fortis Healthcare, Max Healthcare etc. This may affect the company operations and result to company’s loss of market share, finances and demands.

India is on a health care mission to improve its facilities and implement better treatments. The company’s vision is to promote and access better health care in India. The Indian eye care industry has shown remarkable growth in the past few years and is projected to increase at a compound annual growth rate of 12% to 14% from 2024 to 2028. The company has shown healthy profits from its operations over the last three fiscal years but also faces strong competition by well established companies in this sector. Potential investors should access the risks given in the RHP draft before investing.

The company with the help of this IPO seeks to utilize its net proceeds to repay its borrowings, implement the finances for general corporate purposes and pursue unidentified inorganic acquisition. It has shown positive financial growth over the last three fiscal years but faces considerable risks as well. Prospective investors should go through its RHP draft prospectus before investing.